A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Risdiplam (Primary)
- Indications Spinal muscular atrophy
- Focus Therapeutic Use
- Acronyms HINALEA 2
- Sponsors Roche
Most Recent Events
- 06 Aug 2024 Planned initiation date (estimated date of first participant enrollment) changed from 31 May 2024 to 16 Aug 2024.
- 29 Mar 2024 Planned initiation date (estimated date of first participant enrollment) changed from 20 Apr 2024 to 31 May 2024.
- 12 Mar 2024 Planned initiation date (estimated date of first participant enrollment) changed from 12 Mar 2024 to 20 Apr 2024.